EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics will be highlighting its expanding Stanbio clinical chemistry range at Hospitalar, 19-22 May in Sao Paulo, Brazil.
EKF Diagnostics announces the launch of its next generation sequencing technology PrecisionPath™ in partnership with Greenville Health Systems, one of the leading cancer institutes in the US.
Launch of next generation sequencing technology PrecisionPath in partnership with Greenville Health Systems.
EKF Diagnostics, the global diagnostics company, announces that it has introduced the Stanbio Chemistry Procalcitonin (PCT) LiquiColor® assay.
EKF Diagnostics Holdings confirms that the Annual Report and Accounts for the year ended 31 December 2014, the Notice of the Annual General Meeting and a Form of Proxy have been posted to shareholders.
Posting of Annual Report & Notice of AGM.
EKF Diagnostics announces that it has launched its next generation Hemo Control Point of Care (POC) diagnostics analyzer, providing laboratory accurate hemoglobin and hematocrit results in one simple test.
EKF Diagnostics, the global diagnostics company, announces that its PointMan™ DNA enrichment technology has been identified as an easy and useful method for non-invasively determining plasma EGFR T790M mutation status in late stage lung cancer patients.
PointMan™ shown to be a useful method for non-invasively determining plasma EGFR T790M mutation status in late stage lung cancer patients.